Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Movantik
|
| gptkbp:activities |
Opioid receptor antagonist
|
| gptkbp:appointed_by |
Oral tablet
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:brand |
gptkb:Movantik
|
| gptkbp:class |
Opioid antagonists
|
| gptkbp:clinical_trial |
Phase III
approximately 3% |
| gptkbp:contraindication |
Known hypersensitivity to naloxegol
Severe hepatic impairment |
| gptkbp:developed_by |
gptkb:temple
|
| https://www.w3.org/2000/01/rdf-schema#label |
Naloxegol
|
| gptkbp:ingredients |
C24 H29 N3 O5 S
|
| gptkbp:is_atype_of |
A06 A D15
|
| gptkbp:is_used_for |
Opioid-induced constipation
|
| gptkbp:manager |
Oral
|
| gptkbp:side_effect |
gptkb:Nausea
Diarrhea Headache Abdominal pain Flatulence |
| gptkbp:type_of |
863254-16-9
|